This podcast episode featuring Jini Glaros, Chief Scientific Officer of Modern Canna Labs, explores the dynamics of THC inflation and lab shopping in the cannabis industry. With a rich background in biochemistry and cannabis science, Jini demystifies the complex factors driving this phenomenon and its far-reaching consequences.

THC inflation refers to the practice of artificially inflating reported THC levels in cannabis products. Producers seek out labs willing to provide inflated results, leading to an alarming trend of misleading information. Glaros highlights the risks associated with THC inflation, including reputational damage and loss of consumer confidence.

The podcast also delves into strategies to counteract THC inflation and lab shopping. Glaros notes the emergence of state-run labs to verify data from cannabis labs and the implementation of standardized methods. She underscores the need for continued efforts to curb these practices and proposes measures like second-lab verification, round-robin testing, and stricter penalties to discourage labs from engaging in such actions. She also emphasizes the role of education and reckons that empowering consumers with an understanding of factors contributing to cannabis potency, beyond just THC, equips them to make informed choices and identify deceptive claims.Tune in to the conversation for these and more such insightful nuggets.

Key Takeaways

• What are THC inflation and lab shopping?
• What are the risks associated with these practices?
• How do businesses, labs, consumers, and the industry at large suffer due to THC inflation?
• What are the strategies the industry can adopt to arrest THC inflation and lab shopping?
• What are some steps labs can take, what are the red flags consumers can look out for, and what jurisdictions can states bring in?
• How do dry weight corrections impact potency values?